Research Paper Volume 12, Issue 7 pp 5792—5811
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
Figure 4. Overall survival and disease free survival according to risk groups (low-risk vs intermediate-risk vs high-risk). (A) Overall survival in low-, intermediate- and high-risk patients. (B) Disease free survival in low-, intermediate- and high-risk patients.